TY - JOUR
T1 - Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
AU - Avivi, Irit
AU - Vesole, David H.
AU - Davila-Valls, Julio
AU - Usnarska-Zubkiewicz, Lidia
AU - Olszewska-Szopa, Magdalena
AU - Milunovic, Vibor
AU - Baumert, Bartłomiej
AU - Osękowska, Bogumiła
AU - Kopińska, Anna
AU - Gentile, Massimo
AU - Puertas-Martinez, Borja
AU - Robak, Paweł
AU - Crusoe, Edvan
AU - Rodriguez-Lobato, Luis Gerardo
AU - Gajewska, Małgorzata
AU - Varga, Gergely
AU - Delforge, Michel
AU - Cohen, Yael
AU - Gozzetti, Alessandro
AU - Pena, Camila
AU - Shustik, Chaim
AU - Mikala, Gabor
AU - Zalac, Klara
AU - Alexander, H. Denis
AU - Barth, Peter
AU - Weisel, Katja
AU - Martínez-López, Joaquín
AU - Waszczuk-Gajda, Anna
AU - Krzystański, Mateusz
AU - Jurczyszyn, Artur
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational ‘real-world’ retrospective study analyzed the characteristics and outcomes of MM patients that developed SPMs. Results: 165 patients were analyzed: 62.4% males; 8.5% with a prior cancer; 113 with solid SPMs, mainly ≥stage 2; and 52 with hematological SPM (hemato-SPM), mainly MDS/AML. Patients with hemato-SPM were younger (p = 0.05) and more frequently had a prior AutoHCT (p = 0.012). The time to SPM was shorter in the older (>65 years) and more heavily pretreated patients. One hundred patients were actively treated at the time of SPM detection. Treatment was discontinued in 52, substituted with another anti-MM therapy in 15, and continued in 33 patients. Treatment discontinuation was predominant in the patients diagnosed with hemato-SPM (76%). The median OS following SPM detection was 8.5 months, and the main cause of death was SPM. A poor ECOG status predicted a shorter OS (PS 3 vs. 0, HR = 5.74, 2.32–14.21, p < 0.001), whereas a normal hemoglobin level (HR = 0.43, 0.19–0.95, p = 0.037) predicted longer OS. Conclusions: With the continuing improvement in OS, a higher proportion of MM patients might develop SPM. The OS following SPM diagnosis is poor; hence, frequent surveillance and early detection are imperative to improve outcomes.
AB - Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational ‘real-world’ retrospective study analyzed the characteristics and outcomes of MM patients that developed SPMs. Results: 165 patients were analyzed: 62.4% males; 8.5% with a prior cancer; 113 with solid SPMs, mainly ≥stage 2; and 52 with hematological SPM (hemato-SPM), mainly MDS/AML. Patients with hemato-SPM were younger (p = 0.05) and more frequently had a prior AutoHCT (p = 0.012). The time to SPM was shorter in the older (>65 years) and more heavily pretreated patients. One hundred patients were actively treated at the time of SPM detection. Treatment was discontinued in 52, substituted with another anti-MM therapy in 15, and continued in 33 patients. Treatment discontinuation was predominant in the patients diagnosed with hemato-SPM (76%). The median OS following SPM detection was 8.5 months, and the main cause of death was SPM. A poor ECOG status predicted a shorter OS (PS 3 vs. 0, HR = 5.74, 2.32–14.21, p < 0.001), whereas a normal hemoglobin level (HR = 0.43, 0.19–0.95, p = 0.037) predicted longer OS. Conclusions: With the continuing improvement in OS, a higher proportion of MM patients might develop SPM. The OS following SPM diagnosis is poor; hence, frequent surveillance and early detection are imperative to improve outcomes.
KW - second primary malignancy
KW - SPM
KW - multiple myeloma
KW - therapy
UR - https://www.scopus.com/pages/publications/85170380030
U2 - 10.3390/cancers15174359
DO - 10.3390/cancers15174359
M3 - Article
C2 - 37686635
SN - 2072-6694
VL - 15
SP - 1
EP - 14
JO - Cancers
JF - Cancers
IS - 17
M1 - 4359
ER -
